Form 4: LeonaBio Director Fred Callori Receives Stock Options
Director Equity Grant
Director Fred Callori was granted 56,000 stock options in LeonaBio, Inc. as part of the company's 2026 Equity Incentive Plan.
Summary
- Director Fred Callori acquired 56,000 stock options in LeonaBio, Inc. (LONA).
- The options have an exercise price of $9.63 per share.
- The grant date for these options is May 5, 2026.
- The options are scheduled to expire on May 4, 2036.
- Vesting occurs monthly over a 36-month period, contingent upon continued service.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Standardized vesting schedule encourages long-term retention of key leadership.
Negatives
- Issuance of stock options results in potential future dilution for existing shareholders.
Risks
- Dilution of equity if options are exercised.
- Dependence on continued service of the director to fulfill vesting requirements.
Future Outlook
The options vest monthly over 36 months, indicating a long-term commitment to the company's equity incentive structure.
Management Comments
- The options are subject to the terms of the Issuer's 2026 Equity Incentive Plan.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure leadership remains incentivized during long R&D cycles.
Comparison to Industry Standards
- The 36-month vesting schedule is consistent with standard industry practices for board-level equity compensation.
- Granting options at market price is a standard mechanism to align director incentives with shareholder returns.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Incentive Plan | Grant of options under the 2026 Equity Incentive Plan. | 05/05/2026 | Standard compensation practice to align director interests. |
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise of these options.
Next Steps
- Vesting of options on a monthly basis starting from May 2026.
Key Dates
| Date | Description |
|---|---|
| 05/05/2026 | Transaction date of the stock option grant. |
| 05/07/2026 | Date the Form 4 was signed and filed. |
| 05/04/2036 | Expiration date of the granted stock options. |
Keywords
LeonaBio, LONA, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.